| 0.4301 0.008 (1.82%) | 11-28 15:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.51 | 1-year : | 0.53 |
| Resists | First : | 0.43 | Second : | 0.46 |
| Pivot price | 0.43  |
|||
| Supports | First : | 0.4 | Second : | 0.33 |
| MAs | MA(5) : | 0.42 |
MA(20) : | 0.43 |
| MA(100) : | 0.48 |
MA(250) : | 0.64 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 36.2 |
D(3) : | 39.3 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 2.32 | Low : | 0.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NRBO ] has closed above bottom band by 29.2%. Bollinger Bands are 75.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.45 - 0.45 | 0.45 - 0.46 |
| Low: | 0.41 - 0.42 | 0.42 - 0.42 |
| Close: | 0.42 - 0.42 | 0.42 - 0.43 |
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Mon, 13 Nov 2023
NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial ... - PR Newswire
Mon, 06 Nov 2023
NeuroBo Pharmaceuticals Strengthens Board of Directors with the ... - PR Newswire
Tue, 17 Oct 2023
NeuroBo to Present at the H.C. Wainwright 7th Annual NASH ... - PR Newswire
Fri, 29 Sep 2023
The Zacks Analyst Blog Highlights Molina Healthcare, Dr. Reddy's Laboratories and NeuroBo Pharmaceuticals - Yahoo Finance
Fri, 15 Sep 2023
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a ... - PR Newswire
Wed, 02 Aug 2023
NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera ... - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 39 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 50.1 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 90 (K) |
| Shares Short P.Month | 122 (K) |
| EPS | -5.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.56 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.8 % |
| Return on Equity (ttm) | -86.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.08 |
| PEG Ratio | 0 |
| Price to Book value | 0.76 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|